See more : uWink Inc. Del (UWKI) Income Statement Analysis – Financial Results
Complete financial analysis of QuidelOrtho Corporation (QDEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of QuidelOrtho Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Villa Kunalai Public Company Limited (KUN.BK) Income Statement Analysis – Financial Results
- Mitsubishi Shokuhin Co., Ltd. (7451.T) Income Statement Analysis – Financial Results
- Oxford Lane Capital Corp. (OXLCP) Income Statement Analysis – Financial Results
- Lightning eMotors, Inc. (ZEV-WT) Income Statement Analysis – Financial Results
- Doma Holdings Inc. (DOMA-WT) Income Statement Analysis – Financial Results
QuidelOrtho Corporation (QDEL)
About QuidelOrtho Corporation
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00B | 3.27B | 1.70B | 1.66B | 534.89M | 522.29M | 277.74M | 191.60M | 196.13M | 182.62M | 175.41M | 155.74M | 158.60M | 113.34M | 164.28M | 128.13M | 118.07M | 106.02M | 92.30M | 78.69M | 95.11M | 76.27M | 74.06M | 68.35M | 47.20M | 45.70M | 41.90M | 34.50M | 31.10M | 28.40M | 27.70M | 26.50M | 27.80M | 9.00M | 8.70M | 6.10M | 7.50M | 9.50M |
| Cost of Revenue | 1.50B | 1.33B | 427.66M | 312.81M | 214.09M | 206.57M | 121.60M | 73.41M | 71.69M | 74.18M | 66.98M | 61.29M | 62.87M | 52.61M | 55.22M | 50.21M | 48.57M | 44.82M | 37.10M | 35.23M | 42.81M | 38.27M | 35.27M | 36.50M | 22.80M | 21.10M | 17.20M | 13.90M | 14.20M | 13.80M | 13.20M | 12.90M | 13.70M | 3.70M | 5.30M | 4.30M | 8.60M | 3.60M |
| Gross Profit | 1.49B | 1.94B | 1.27B | 1.35B | 320.81M | 315.71M | 156.14M | 118.19M | 124.44M | 108.44M | 108.43M | 94.46M | 95.74M | 60.73M | 109.06M | 77.93M | 69.49M | 61.20M | 55.20M | 43.46M | 52.29M | 38.01M | 38.78M | 31.85M | 24.40M | 24.60M | 24.70M | 20.60M | 16.90M | 14.60M | 14.50M | 13.60M | 14.10M | 5.30M | 3.40M | 1.80M | -1.10M | 5.90M |
| Gross Profit Ratio | 49.85% | 59.28% | 74.82% | 81.17% | 59.98% | 60.45% | 56.22% | 61.68% | 63.45% | 59.38% | 61.82% | 60.65% | 60.36% | 53.58% | 66.39% | 60.82% | 58.86% | 57.72% | 59.80% | 55.22% | 54.98% | 49.83% | 52.37% | 46.59% | 51.69% | 53.83% | 58.95% | 59.71% | 54.34% | 51.41% | 52.35% | 51.32% | 50.72% | 58.89% | 39.08% | 29.51% | -14.67% | 62.11% |
| Research & Development | 246.80M | 190.50M | 95.70M | 84.29M | 52.55M | 51.65M | 33.64M | 38.67M | 35.51M | 37.91M | 34.19M | 27.72M | 26.33M | 24.57M | 12.53M | 11.15M | 12.86M | 13.05M | 12.83M | 11.34M | 8.47M | 6.75M | 6.20M | 7.05M | 7.90M | 7.90M | 6.70M | 4.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 748.10M | 594.20M | 84.25M | 66.59M | 52.76M | 44.95M | 29.19M | 27.06M | 29.45M | 25.81M | 26.26M | 20.64M | 22.80M | 18.47M | 16.78M | 12.79M | 31.66M | 29.74M | 29.18M | 28.84M | 28.51M | 25.85M | 0.00 | 8.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.10M | 26.80M | 175.33M | 133.96M | 111.11M | 108.99M | 67.25M | 47.82M | 47.89M | 41.53M | 33.83M | 30.32M | 25.75M | 23.97M | 23.35M | 20.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 763.20M | 621.00M | 259.57M | 200.54M | 163.87M | 153.94M | 96.44M | 74.88M | 77.33M | 67.34M | 60.09M | 50.96M | 48.55M | 42.44M | 40.13M | 33.68M | 31.66M | 29.74M | 29.18M | 28.84M | 28.51M | 25.85M | 24.49M | 25.19M | 15.80M | 15.70M | 14.20M | 13.90M | 18.90M | 16.00M | 13.20M | 11.70M | 17.50M | 4.70M | 5.60M | 5.90M | 7.20M | 5.50M |
| Other Expenses | 345.30M | 144.80M | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 9.07M | 8.86M | 8.83M | 31.00K | -30.00K | 7.12M | 6.73M | 1.36M | 4.48M | 5.49M | 4.58M | 18.48M | 1.46M | 2.06M | 1.95M | 4.37M | 1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.36B | 956.30M | 355.27M | 284.84M | 216.42M | 205.59M | 130.08M | 122.63M | 121.70M | 114.09M | 102.44M | 85.61M | 82.00M | 73.75M | 54.02M | 49.31M | 50.01M | 47.36M | 60.49M | 41.64M | 39.03M | 34.54M | 35.06M | 34.21M | 27.00M | 26.70M | 23.40M | 20.10M | 20.80M | 17.50M | 14.50M | 13.10M | 19.30M | 5.20M | 6.20M | 6.50M | 7.70M | 6.00M |
| Cost & Expenses | 2.86B | 2.29B | 782.93M | 597.65M | 430.51M | 412.16M | 251.69M | 196.04M | 193.39M | 188.27M | 169.42M | 146.90M | 144.86M | 126.35M | 109.24M | 99.51M | 98.58M | 92.18M | 97.59M | 76.88M | 81.84M | 72.81M | 70.33M | 70.72M | 49.80M | 47.80M | 40.60M | 34.00M | 35.00M | 31.30M | 27.70M | 26.00M | 33.00M | 8.90M | 11.50M | 10.80M | 16.30M | 9.60M |
| Interest Income | 2.20M | 1.30M | 300.00K | 600.00K | 14.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 41.00K | 203.00K | 214.00K | 372.00K | 1.69M | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 178.90M | 75.70M | 5.71M | 9.62M | 14.79M | 24.28M | 17.59M | 11.76M | 12.04M | 1.78M | 777.00K | 1.25M | 2.08M | 2.35M | 767.00K | 671.00K | 736.00K | 0.00 | 17.92M | 0.00 | 4.55M | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 457.20M | 283.60M | 54.38M | 49.09M | 51.79M | 46.27M | 30.76M | 31.87M | 8.86M | 8.83M | 8.17M | 6.94M | 7.12M | 6.73M | 1.36M | 4.48M | 9.85M | 9.11M | 5.47M | 6.21M | 6.60M | 6.15M | 8.15M | 6.53M | 3.30M | 3.10M | 2.50M | 2.10M | 1.90M | 1.50M | 1.30M | 1.40M | 1.80M | 500.00K | 600.00K | 600.00K | 500.00K | 500.00K |
| EBITDA | 607.00M | 1.09B | 955.44M | 1.09B | 143.76M | 133.93M | 40.31M | 18.78M | 11.59M | 19.16M | 29.74M | 15.79M | 31.38M | -2.75M | 59.28M | 39.12M | 31.11M | 22.94M | 176.00K | 7.37M | 21.19M | 11.71M | 10.43M | 5.21M | 600.00K | 900.00K | 3.80M | 2.50M | -2.00M | -1.40M | 1.00M | 1.90M | -3.40M | 600.00K | -2.20M | -4.10M | -8.30M | 400.00K |
| EBITDA Ratio | 20.25% | 33.81% | 53.91% | 64.03% | 19.51% | 21.09% | 9.38% | 2.42% | 5.91% | 1.74% | 8.10% | 10.14% | 13.28% | -5.35% | 34.56% | 27.14% | 24.95% | 21.13% | 18.56% | 9.36% | 22.77% | 10.00% | 14.08% | 6.22% | -7.84% | -0.44% | 1.91% | 5.22% | -8.68% | -9.86% | 3.61% | 3.02% | -14.39% | 15.56% | -27.59% | -27.87% | -120.00% | 2.11% |
| Operating Income | 139.10M | 843.70M | 906.07M | 1.06B | 52.59M | 95.93M | 9.55M | -4.44M | 2.74M | -9.21M | 4.17M | 8.85M | 13.74M | -15.29M | 52.55M | 28.62M | 19.49M | 13.83M | -5.29M | 1.82M | 11.06M | 3.47M | 3.18M | -4.67M | -2.60M | -2.10M | 1.30M | 500.00K | -3.90M | -2.90M | -300.00K | 500.00K | -5.20M | 100.00K | -2.80M | -4.70M | -8.80M | -100.00K |
| Operating Income Ratio | 4.64% | 25.83% | 53.34% | 63.81% | 9.83% | 18.37% | 3.44% | -2.32% | 1.40% | -5.04% | 2.37% | 5.68% | 8.66% | -13.49% | 31.99% | 22.34% | 16.50% | 13.05% | -5.73% | 2.31% | 11.63% | 4.54% | 4.29% | -6.83% | -5.51% | -4.60% | 3.10% | 1.45% | -12.54% | -10.21% | -1.08% | 1.89% | -18.71% | 1.11% | -32.18% | -77.05% | -117.33% | -1.05% |
| Total Other Income/Expenses | -168.20M | -107.80M | -5.70M | -20.01M | 24.59M | -32.55M | -17.59M | -11.76M | -12.04M | -1.78M | -1.41M | -1.24M | -2.26M | -2.13M | -400.00K | 1.15M | 1.04M | 1.20M | -37.00K | -232.00K | -573.00K | 2.11M | 19.00K | -1.16M | 4.10M | 700.00K | 2.30M | -400.00K | 700.00K | 1.40M | 700.00K | 400.00K | 600.00K | -800.00K | 200.00K | -2.40M | 700.00K | 100.00K |
| Income Before Tax | -29.10M | 735.90M | 900.36M | 1.04B | 77.18M | 63.38M | -8.04M | -16.20M | -9.30M | -10.98M | 3.43M | 7.61M | 11.48M | -17.42M | 52.15M | 29.77M | 20.52M | 15.03M | -5.33M | 1.58M | 10.50M | 2.84M | 3.86M | -4.78M | 1.40M | -1.50M | 3.60M | 1.30M | -3.20M | -1.50M | 700.00K | 900.00K | -4.60M | -700.00K | -2.60M | -7.10M | -8.10M | 100.00K |
| Income Before Tax Ratio | -0.97% | 22.53% | 53.01% | 62.61% | 14.43% | 12.14% | -2.89% | -8.45% | -4.74% | -6.01% | 1.96% | 4.89% | 7.24% | -15.37% | 31.74% | 23.23% | 17.38% | 14.18% | -5.77% | 2.01% | 11.04% | 3.72% | 5.21% | -6.99% | 2.97% | -3.28% | 8.59% | 3.77% | -10.29% | -5.28% | 2.53% | 3.40% | -16.55% | -7.78% | -29.89% | -116.39% | -108.00% | 1.05% |
| Income Tax Expense | -19.00M | 187.20M | 196.13M | 230.03M | 4.26M | -10.80M | 129.00K | -2.39M | -3.22M | -3.91M | -3.96M | 2.62M | 3.85M | -6.15M | 19.27M | 10.92M | 6.89M | -5.89M | 3.00M | 7.45M | -9.15M | 1.55M | 3.00M | 2.32M | -6.30M | -2.60M | 100.00K | -100.00K | 200.00K | -900.00K | 300.00K | 400.00K | 300.00K | 1.30M | 300.00K | 2.60M | -700.00K | 0.00 |
| Net Income | -10.10M | 548.70M | 704.20M | 810.29M | 72.92M | 74.18M | -8.17M | -13.81M | -6.08M | -7.07M | 7.39M | 4.99M | 7.63M | -11.27M | 32.88M | 18.85M | 13.63M | 21.72M | -9.26M | -6.29M | 19.65M | 1.29M | 854.00K | -5.85M | 7.70M | 1.10M | 3.50M | 600.00K | -4.10M | -2.00M | 700.00K | 800.00K | -5.50M | -1.20M | -3.10M | -7.30M | -8.10M | -100.00K |
| Net Income Ratio | -0.34% | 16.80% | 41.46% | 48.76% | 13.63% | 14.20% | -2.94% | -7.21% | -3.10% | -3.87% | 4.21% | 3.21% | 4.81% | -9.94% | 20.02% | 14.71% | 11.55% | 20.49% | -10.03% | -7.99% | 20.66% | 1.69% | 1.15% | -8.55% | 16.31% | 2.41% | 8.35% | 1.74% | -13.18% | -7.04% | 2.53% | 3.02% | -19.78% | -13.33% | -35.63% | -119.67% | -108.00% | -1.05% |
| EPS | -0.15 | 9.66 | 16.74 | 19.24 | 1.78 | 1.74 | -0.24 | -0.42 | -0.18 | -0.21 | 0.22 | 0.15 | 0.23 | -0.39 | 1.10 | 0.59 | 0.43 | 0.66 | -0.28 | -0.20 | 0.67 | 0.04 | 0.01 | -0.23 | 0.32 | 0.05 | 0.16 | 0.03 | -0.21 | -0.11 | 0.04 | 0.05 | -0.45 | -0.33 | -0.86 | -2.04 | -2.31 | -0.03 |
| EPS Diluted | -0.15 | 9.56 | 16.43 | 18.60 | 1.73 | 1.74 | -0.24 | -0.42 | -0.18 | -0.21 | 0.21 | 0.15 | 0.23 | -0.39 | 1.08 | 0.58 | 0.41 | 0.63 | -0.28 | -0.19 | 0.65 | 0.04 | 0.01 | -0.23 | 0.32 | 0.05 | 0.16 | 0.03 | -0.21 | -0.11 | 0.04 | 0.05 | -0.45 | -0.33 | -0.86 | -2.04 | -2.31 | -0.03 |
| Weighted Avg Shares Out | 66.80M | 56.80M | 42.08M | 42.12M | 40.86M | 42.55M | 33.73M | 32.71M | 33.77M | 33.69M | 34.94M | 33.70M | 32.90M | 28.58M | 29.96M | 31.85M | 32.03M | 32.99M | 32.53M | 31.49M | 29.18M | 28.82M | 28.29M | 24.88M | 24.06M | 22.00M | 22.00M | 20.00M | 19.52M | 18.18M | 17.50M | 14.00M | 12.34M | 3.61M | 3.60M | 3.58M | 3.51M | 3.33M |
| Weighted Avg Shares Out (Dil) | 66.80M | 57.40M | 42.87M | 43.59M | 43.11M | 42.55M | 33.73M | 32.71M | 34.10M | 34.45M | 34.95M | 33.70M | 33.32M | 28.58M | 30.42M | 32.61M | 33.00M | 34.37M | 32.53M | 32.39M | 30.37M | 29.63M | 29.28M | 24.88M | 24.06M | 22.00M | 22.79M | 20.00M | 19.52M | 18.18M | 17.50M | 14.00M | 12.34M | 3.61M | 3.60M | 3.58M | 3.51M | 3.33M |
QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q2 2024 Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Juliet Cunningham - Vice President-Investor Relations Brian Blaser - President & Chief Executive Officer Joe Busky - Chief Financial Officer Conference Call Participants...
QuidelOrtho (QDEL) Reports Q2 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to earnings of $0.26 per share a year ago.
Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600
NEW YORK , July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and...
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
QUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. is Investigating QuidelOrtho Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against QuidelOrtho Corporation (NASDAQ: QDEL) on behalf of long-term stockholders following a class action complaint that...
The Schall Law Firm Encourages Investors Who Have Suffered Losses In QuidelOrtho Corporation To Make Contact
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--DEADLINE TODAY: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm.
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrtho
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL) and reminds investors of the June 11, 2024 deadline...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 11, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired QuidelOrtho Corporation (“QuidelOrtho” or the...
DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm.
Source: https://incomestatements.info
Category: Stock Reports